Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Homebased Medication Review

- candidate number2702
- NTR NumberNTR1036
- Date ISRCTN created5-sep-2007
- date ISRCTN requested31-aug-2007
- Date Registered NTR14-aug-2007
- Secondary IDs 
- Public TitleHomebased Medication Review
- Scientific TitleEvaluation of homebased medication review by community pharmacists in elderly people: a randomised controlled trial
- hypothesisAn homebased medication review intervention conducted by a community pharmacists in close collaboration with the GP and patient improves the quality of pharmacotherapy in elderly patients.
- Healt Condition(s) or Problem(s) studiedMedication review, Drug related problems, Pharmacist, Home visit
- Inclusion criteria1. Persons aged 65 years or older; 2. Prescribed 5 or more regular medicines, including at least one cardiovascular or antidiabetic drug
- Exclusion criteria1. Persons receiving repeat prescriptions solely from a specialist
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlPlacebo
- groupParallel
- Type[default]
- Studytypeintervention
- planned startdate 1-sep-2007
- planned closingdate1-sep-2009
- Target number of participants400
- InterventionsA medication review will be performed by the patientís pharmacist, using the medication list and GP clinical records. The medication review is evaluated and, if necessary, completed by an independent pharmacist panel. All potential drug related problems are identified and classified. The pharmacist visits the patient at home for an interview about the patientís medicines and to identify other possible drug related problems. The medication review will be completed using the information from the patientís interview. Adjustments in pharmacotherapy will be proposed and discussed with the patientís GP. A treatment plan will be formulated. The GP or pharmacist will discuss the treatment plan with the patient. Patients in the control group receive regular care.
- Primary outcome1. The number of drug related problems per patient; 2. The number of patients achieving target levels concerning blood pressure, cholesterol and HbA1C;
- Secondary outcome1. The number of patient being treated optimally according to clinical guidelines; 2. The number of medicines per patient; 3. The number unplanned hospital admissions; 4. Change in mean values for HBA1C, cholesterol level and/or blood pressure; 5. Quality of life; 6. Satisfaction of GPs, pharmacists and patient with the intervention; 7. The capability of pharmacists to perform a comprehensive medication review
- Timepoints
- Trial web site
- statusstopped: trial finished
- Sponsor/Initiator LLOYDS Apotheken
- Funding
(Source(s) of Monetary or Material Support)
AstraZeneca, Menzis Zorgverzekeraar, LLOYDS Apotheken, Achmea, KNMP
- Publications
- Brief summaryThe recently published HARM study found that 2,4% of all hospital admissions and 5,6% of all acute admissions in the Netherlands were drug related. Of these admissions 46% were considered ďpossibly avoidableĒ. Drug related problems are a considerable risk for patient safety, especially among patients using multiple chronic medicines. Regular and systematic review of individual patientís drug treatment can help to reduce the number of drug related problems en may improve patient outcome. The Homebased Medication Review project of LLOYDS Pharmacies is based on the Australian Home Medicines Review (HMR). During this project a pharmacy-led medication review will be performed based on the patientís medication list, GP clinical notes and information from a patientís home-interview. The intervention will be performed and monitored by a community pharmacist in close collaboration with the patientís GP. The present study examines the possibility to implement the FTC intervention in primary care in the Netherlands and the effect of the FTC intervention on the quality of pharmacotherapy and clinical outcomes.
- Main changes (audit trail)
- RECORD14-aug-2007 - 11-feb-2013

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar